Circadian variations in exsorptive transport: In situ intestinal perfusion data and in vivo relevance

Chronobiology International

Volumn 29, Issue 4, 2012, Pages 443-453

  Okyar, Alper ^a,b   Dressler, Cornelia ^c   Hanafy, Abeer ^d,e   Baktir, Gül ^a   Lemmer, Björn ^f   Spahn Langguth, Hilde ^b,g  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF GRAZ   (Austria)

^c MUNDIPHARMA GMBH   (Germany)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e Kafrelsheikh University   (Egypt)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g German University in Cairo   (Egypt)

Author keywords

Chronopharmacokinetics; Circadian rhythm; Intestinal perfusion; Losartan; P glycoprotein; Talinolol

Indexed keywords

CYCLOSPORIN DERIVATIVE; GLYCOPROTEIN P; LOSARTAN; PROPANOLAMINE DERIVATIVE; TALINOLOL; VALSPODAR; VINBLASTINE;

ANIMAL; ANIMAL BEHAVIOR; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL RHYTHM; BLOOD; CIRCADIAN RHYTHM; DRUG EFFECT; DRUG INTERACTION; ILEUM; INTESTINE ABSORPTION; JEJUNUM; MALE; METABOLISM; MOTOR ACTIVITY; PERFUSION; PERMEABILITY; PHOTOPERIODICITY; RAT; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; BIOLOGICAL CLOCKS; CIRCADIAN RHYTHM; CYCLOSPORINS; DRUG INTERACTIONS; ILEUM; INTESTINAL ABSORPTION; JEJUNUM; LOSARTAN; MALE; MOTOR ACTIVITY; P-GLYCOPROTEIN; PERFUSION; PERMEABILITY; PHOTOPERIOD; PROPANOLAMINES; RATS; RATS, WISTAR; VINBLASTINE;

EID: 84860110566     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2012.668996     Document Type: Article

References (56)

1. Achira M, Suzuki H, Ito K, Sugiyama Y. (1999). Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharm. Sci. 1:14-19
2. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420
3. Ando H, Yanagihara H, Sugimoto K, Hayashi Y, Tsuruoka S, Takamura T. (2005). Daily rhythms of P-glycoprotein expression in mice. Chronobiol. Int. 22:655-665 (Pubitemid 41361729)
4. Bardelmeijer HA, Beijnen JH, Brouwer KR, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O. (2000). Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6:4416-4421
5. Belanger PM, Bruguerolle B, Labrecque G. (1997). Rhythms in pharmacokinetics: absorption, distribution, metabolism, and excretion. In Redfern P, Lemmer B (eds.). Physiology and pharmacology of biological rhythms. Berlin: Springer, 177-204
6. Bramlage P, Schindler C. (2010). Differences in pharmacology and their translation into differences in clinical efficacy-a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opin. Pharmacother. 11:521-535
7. Bruguerolle B. (2008). Clinical chronopharmacology in the elderly. Chronobiol. Int. 25:1-15 (Pubitemid 351300153)
8. Bruguerolle B, Bouvenot G, Bartolin R, Manolis J. (1988). Chronopharmacokinetics of digoxin in patients over 70 years of age. Therapie 43:251-253
9. Claudel T, Cretenet G, Saumet A, Gachon F. (2007). Crosstalk between xenobiotics metabolism and circadian clock. FEBS Lett. 581:3626-3633 (Pubitemid 47080999)
10. Doluisio JT, Billups NF, Dittert LW, Sugita ET, Swintosky JV. (1969). Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. J. Pharm. Sci. 58:1196-200
11. Dressler C. (2002). Interactions of losartan and its major metabolite EXP3174 with membrane transporters in vitro, in situ, and in vivo. PhD Dissertation, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany
12. Erol K, Kilic FS, Batu OS, Yildirim E. (2001). Morning-evening administration time differences in digoxin kinetics in healthy young subjects. Chronobiol. Int. 18:841-849 (Pubitemid 33139505)
13. Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, Li Q, Lei HP, Jiang F, Hu DL, Huang YF, Zhou HH. (2009). Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann. Pharmacother. 43:944-949
14. Fischer V, Rodríguez-Gascón A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE. (1998). The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26:802-811 (Pubitemid 28376441)
15. Furukawa T, Manabe S, Ohashi Y, Sharyo S, Kimura K, Mori Y. (1999). Daily fluctuation of 7-alkoxycoumarin O-dealkylase activities in the liver of male F344 rats under ad libitum-feeding or fasting condition. Toxicol. Lett. 108:11-16 (Pubitemid 29333105)
16. Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. (2006). The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4:25-36 (Pubitemid 43942254)
17. Goo RH, Moore JG, Greenberg E, Alazraki NP. (1987). Circadian variation in gastric emptying of meals in humans. Gastroenterology 93:515-518 (Pubitemid 17119244)
18. Hanafy A. (2001). Transport inhibition and induction as sources for absorption- and disposition-related drug-drug interactions: talinolol as model substrate for ABC transporter P-glycoprotein. PhD Dissertation, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany
19. Hanafy A, Langguth P, Spahn-Langguth H. (2001). Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur. J. Pharm. Sci. 12:405-415 (Pubitemid 32166739)
20. Hayashi Y, Ushijima K, Ando H, Yanagihara H, Ishikawa E, Tsuruoka S, Sugimoto K, Fujimura A. (2010). Influence of a time-restricted feeding schedule on the daily rhythm of abcb1a gene expression and its function in rat intestine. J. Pharmacol. Exp. Ther. 335:418-423
21. Ho KJ, Drummond JL. (1975). Circadian rhythm of biliary excretion and its control mechanisms in rats with chronic biliary drainage. Am. J. Physiol. 229:1427-1437
22. Klaassen CD, Aleksunes LM. (2010). Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 62:1-96
23. Lemmer B. (1999). Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol. 51:887-890 (Pubitemid 29431399)
24. Lemmer B, Bruguerolle B. (1994). Chronopharmacokinetics. Are they clinically relevant? Clin. Pharmacokinet. 26:419-427 (Pubitemid 24166332)
25. Lemmer B, Nold G. (1991). Circadian changes in estimated hepatic blood flow in healthy subjects. Br. J. Clin. Pharmacol. 32:627-629
26. Lemmer B, Caspari-Irving G, Weimer R. (1981). Strain-dependency in motor activity and in concentration and turnover of catecholamines in synchronized rats. Pharmacol. Biochem. Behav. 15:173-178 (Pubitemid 11054610)
27. Lemmer B, Nold G, Behne S, Kaiser R. (1991). Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol. Int. 8:485-494
28. Lemmer B, Dressler C, Okyar A, Baktir G, Spahn-Langguth H. (2004). Circadian variations in effective permeabilities of talinolol and losartan in rats: metabolism- or transport-related? Naunyn Schmiedeberg. Arch. Pharmacol. 369(Suppl 1):R103/412
29. Lévi F, Schibler U. (2007). Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47:593-628
30. Lévi F, Metzger G, Massari C, Milano G. (2000). Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38:1-21 (Pubitemid 30055088)
31. Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. (2010). Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50:377-419
32. MacLean C, Moenning U, Reichel A, Fricker G. (2008). Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab. Dispos. 36:1249-1254 (Pubitemid 351929307)
33. Martin C, Dutertre-Catella H, Radionoff M, Debray M, Benstaali C, Rat P, Thevenin M, Touitou Y, Warnet JM. (2003). Effect of age and photoperiodic conditions on metabolism and oxidative stress related markers at different circadian stages in rat liver and kidney. Life Sci. 73:327-335 (Pubitemid 36579175)
34. Murakami Y, Higashi Y, Matsunaga N, Koyanagi S, Ohdo S. (2008). Circadian clock-controlled intestinal expression of the multidrugresistance gene mdr1a in mice. Gastroenterology 135:1636-1644
35. Oertel R, Richter K, Trausch B, Berndt A, Gramatte T, Kirch W. (1994). Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J. Chromatogr. B 660:353-363 (Pubitemid 24318802)
36. Okyar A. (2004). Investigation of interaction between talinolol-vinblastine and talinolol-atorvastatin through P-glycoprotein. Ph.D. dissertation, Department of Pharmacology, Institute of Health Science, Istanbul University, Istanbul, Turkey
37. Okyar A, Filipski E, Dulong S, Ahowesso C, Li XM, Levi F. (2009). Rhythmic intestinal drug elimination via ABC transporters: a potential determinant of anticancer drugs chronopharmacology. In 11th Congress of European Biological Rhythm Society, Strasbourg, France. August 22-29. Program and abstract book, 153
38. Okyar A, Piccolo E, Ahowesso C, Filipski E, Hossard V, Guettier C, La Sorda R, Tinari N, Iacobelli S, Lévi F. (2011). Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS ONE 6(6):e20393
39. Pons M, Tranchot J, LAzou B, Cambar J. (1994). Circadian rhythms of renal hemodynamics in unanesthetized, unrestrained rats. Chronobiol. Int. 11:301-308
40. Pons M, Schnecko A, Witte K, Lemmer B, Waterhouse JM, Cambar J. (1996). Circadian rhythms in renal function in hypertensive TGR (mRen-2)27 rats and their normotensive controls. Am. J. Physiol. 271:R1002-R1008
41. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911-1929
42. Sachs L. (1978). Applied statistics (pp. 230-235). Berlin: Springer
43. Sandström R, Lennernäs H. (1999). Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats. Drug Metab. Dispos. 27:951-958
44. Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I. (2009). Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res. 26:560-567
45. Sinko P.J, Leesman G.D, Amidon G.L. (1991). Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8:979-988
46. Spahn-Langguth H, Langguth P. (2001). Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12:361-367 (Pubitemid 32166734)
47. Spahn-Langguth H, Bakt?r G, Radschuweit A., Okyar A., Terhaag B., Ader P, Hanafy A, Langguth P. (1998). P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:16-24 (Pubitemid 28031804)
48. Stearns A, Balakrishnan A, Rhoads D, Ashley S. (2008). Diurnal rhytmicity in the transcription of jejunal drug transporters. J. Pharm. Sci. 108:144-148
49. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesmann MM. (2006). Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 3:219-234 (Pubitemid 43336035)
50. Therapeutic Systems Research Lab. Inc. http://www.tsrlinc.com. Accessed October 28, 2011
51. Trausch B, Oertel R, Richter K, Gramatte T. (1995). Disposition and bioavailability of the ?1-adrenoceptor antagonist talinolol in man. Biopharm. Drug Dispos. 16:403-414
52. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:514-522 (Pubitemid 26119052)
53. Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22:11-23 (Pubitemid 40558141)
54. Zhang YK, Yeager RL, Klaassen CD. (2009). Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab. Dispos. 37:106-115
55. Zhou XJ, Martin M, Placidi M, Cano JP, Rahmani R. (1990). In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine. Eur. J. Drug Metab. Pharmacokinet. 15:323-332
56. Zschiesche M, Lemma GL, Klebingat KJ, Franke G, Terhaag B, Hoffmann A, Gramatté T, Kroemer HK, Siegmund W. (2002). Stereoselective disposition of talinolol in man. J. Pharm. Sci. 91:303-311 (Pubitemid 34137354)